The U.S. Food and Drug Administration (FDA) granted supplemental approval for Opdivo (nivolumab) on March 20, 2026. This approval, designated as BLA 125554 S-135, was based on new efficacy data, further expanding the therapeutic profile of this important immunotherapy.
Background
Nivolumab, marketed as Opdivo, is an established immunotherapy drug. This supplemental approval for Opdivo falls under the 'Efficacy' class, indicating that the FDA reviewed and accepted new data supporting the drug's effectiveness. Nivolumab is developed and manufactured by Bristol Myers Squibb, the sponsor of this application. Prior to this, nivolumab has received multiple approvals for various cancer indications, establishing its role in oncology. The continuous evaluation of its efficacy through supplemental applications allows for the potential expansion of its approved uses, benefiting a wider range of patients.
What this means
This supplemental approval for Opdivo (nivolumab) signifies that the FDA has evaluated and confirmed additional evidence of the drug's effectiveness. While the specific details of the new indication or patient population are not provided in the approval notice, such approvals typically allow for an expansion of the drug's approved uses. This could mean a new disease area, a different line of therapy, or an expanded patient population for an existing indication. Clinicians should consult the updated prescribing information and drug label for the full details of this new approval, including any changes to dosing, administration, or safety information. This ongoing process of supplemental approvals is crucial for optimizing the use of established therapies in clinical practice.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125554 S-135, concerning Opdivo (nivolumab), was documented on March 20, 2026, on accessdata.fda.gov.